Tvardi Therapeutics (TVRD) Competitors $33.88 -1.52 (-4.29%) As of 09/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVRD vs. STOK, ETNB, XERS, EVO, PGEN, COLL, ZYME, NTLA, RCUS, and TRMLShould you be buying Tvardi Therapeutics stock or one of its competitors? The main competitors of Tvardi Therapeutics include Stoke Therapeutics (STOK), 89BIO (ETNB), Xeris Biopharma (XERS), Evotec (EVO), Precigen (PGEN), Collegium Pharmaceutical (COLL), Zymeworks (ZYME), Intellia Therapeutics (NTLA), Arcus Biosciences (RCUS), and Tourmaline Bio (TRML). These companies are all part of the "pharmaceutical products" industry. Tvardi Therapeutics vs. Its Competitors Stoke Therapeutics 89BIO Xeris Biopharma Evotec Precigen Collegium Pharmaceutical Zymeworks Intellia Therapeutics Arcus Biosciences Tourmaline Bio Stoke Therapeutics (NASDAQ:STOK) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations. Is STOK or TVRD more profitable? Stoke Therapeutics has a net margin of 26.25% compared to Tvardi Therapeutics' net margin of -678.79%. Stoke Therapeutics' return on equity of 18.32% beat Tvardi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics26.25% 18.32% 15.48% Tvardi Therapeutics -678.79%-565.83%-66.71% Do insiders and institutionals have more ownership in STOK or TVRD? 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, STOK or TVRD? Stoke Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Which has better valuation and earnings, STOK or TVRD? Tvardi Therapeutics has lower revenue, but higher earnings than Stoke Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$199.89M6.43-$88.98M$0.8527.60Tvardi TherapeuticsN/AN/A-$70.87MN/AN/A Does the media prefer STOK or TVRD? In the previous week, Stoke Therapeutics had 7 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 8 mentions for Stoke Therapeutics and 1 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 1.89 beat Stoke Therapeutics' score of 1.25 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Stoke Therapeutics Positive Tvardi Therapeutics Very Positive Do analysts prefer STOK or TVRD? Stoke Therapeutics presently has a consensus target price of $25.57, suggesting a potential upside of 9.00%. Tvardi Therapeutics has a consensus target price of $64.25, suggesting a potential upside of 89.64%. Given Tvardi Therapeutics' higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Tvardi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryStoke Therapeutics beats Tvardi Therapeutics on 10 of the 14 factors compared between the two stocks. Get Tvardi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVRD vs. The Competition Export to ExcelMetricTvardi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$331.96M$3.19B$5.84B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E RatioN/A21.4375.4125.98Price / SalesN/A432.54515.86180.60Price / CashN/A46.6837.5660.44Price / Book-11.229.6112.156.29Net Income-$70.87M-$53.29M$3.29B$271.07M7 Day Performance8.90%0.13%0.74%3.87%1 Month Performance42.41%5.55%5.00%5.49%1 Year PerformanceN/A10.44%62.55%25.86% Tvardi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVRDTvardi Therapeutics2.7247 of 5 stars$33.88-4.3%$64.25+89.6%N/A$331.96MN/A0.0080Positive NewsSTOKStoke Therapeutics3.9352 of 5 stars$23.46-1.8%$25.57+9.0%+62.1%$1.31B$199.89M27.60100Positive NewsETNB89BIO2.7939 of 5 stars$8.07-6.7%$28.00+247.0%-4.8%$1.28BN/A-2.2440Positive NewsXERSXeris Biopharma2.7925 of 5 stars$7.49-2.5%$7.08-5.4%+160.1%$1.24B$246.03M-35.66290News CoveragePositive NewsInsider TradeEVOEvotec1.6909 of 5 stars$3.47-0.3%$5.40+55.6%-2.0%$1.24B$777.33M0.004,827PGENPrecigen4.5557 of 5 stars$3.79-8.5%$8.25+117.7%+261.0%$1.23B$3.92M-9.02190Positive NewsCOLLCollegium Pharmaceutical3.7607 of 5 stars$37.32-4.5%$42.33+13.4%-0.5%$1.23B$707.01M35.88210Positive NewsZYMEZymeworks2.4325 of 5 stars$15.74-3.6%$21.43+36.1%+25.5%$1.23B$122.87M-10.49460Positive NewsNTLAIntellia Therapeutics4.387 of 5 stars$11.42flat$27.11+137.4%-48.3%$1.23B$52.86M-2.43600News CoverageAnalyst RevisionRCUSArcus Biosciences2.0161 of 5 stars$11.50flat$21.14+83.9%-36.0%$1.22B$262M-3.63500Positive NewsTRMLTourmaline Bio0.8917 of 5 stars$47.61+0.0%$45.85-3.7%+147.1%$1.22BN/A-13.8844Trending NewsAnalyst Downgrade Related Companies and Tools Related Companies Stoke Therapeutics Alternatives 89BIO Alternatives Xeris Biopharma Alternatives Evotec Alternatives Precigen Alternatives Collegium Pharmaceutical Alternatives Zymeworks Alternatives Intellia Therapeutics Alternatives Arcus Biosciences Alternatives Tourmaline Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVRD) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
